Navigation Links
GPhA Calls Senate HELP Committee Action Disappointing for Countless Patients
Date:7/13/2009

ARLINGTON, Va., July 13 /PRNewswire-USNewswire/ -- The Generic Pharmaceutical Association (GPhA) released the following statement today from GPhA President and CEO Kathleen Jaeger on the Senate HELP Committee's vote on biogenerics legislation.

"While we are extremely disappointed that the Committee action could result in patients having little or no access to affordable biogenerics, we will continue to fight in the House to ensure that a true balance is achieved between innovation and competition. It is surprising that in the wake of the recent Federal Trade Commission report explicitly stating that 12 years of exclusivity would discourage innovation, the HELP Committee voted in favor of profits over patients. This unprecedented action strikes a huge blow to consumers at a time when many Americans are struggling to pay for the medicines they need.

"With generics saving the health care system $734 billion in the last decade, the House must now act to ensure that additional savings can be achieved by rejecting unnecessary and excessive years of market exclusivity for biopharmaceuticals. Over the last two years, we have dispelled the myths on the safety and efficacy of biogenerics that brand PhRMA and BIO tried to make to keep biogenerics from getting to consumers. It is now time to dispel the myth that double-digit years of exclusivity are needed to spark innovation. The White House already has the FDA working on creating a pathway and it has firmly stated that seven years of exclusivity is a good compromise. We must follow the course of the White House and Chairman Waxman and ensure that patients can truly access lifesaving biogeneric medicines in a timely manner.

"We hope that when the House Energy and Commerce Committee acts it follows the lead of its Chairman in approving a market exclusivity period that puts patients first. History has shown that a balance between innovation and competition can be achieved that benefits consumers and industry alike. Chairman Waxman knows this and we encourage him to continue to make patients the priority."

GPhA represents the manufacturers and distributors of finished generic pharmaceuticals, manufacturers and distributors of bulk active pharmaceutical chemicals, and suppliers of other goods and services to the generic drug industry. Generics represent 69% of the total prescriptions dispensed in the United States, but only 16% of all dollars spent on prescription drugs. For more information about the industry, visit www.gphaonline.org.


'/>"/>
SOURCE Generic Pharmaceutical Association
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
2. World Hepatitis Alliance Calls on Governments to Take Urgent Action to Tackle Chronic Viral Hepatitis B & C Epidemic
3. ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets
4. International Diabetes Federation Calls for Global Action to Keep All Children With Diabetes Alive
5. Kaiser Permanente CEO Calls for Connected Health Care
6. Biotechnology Value Fund, L.P. Calls Special Meeting of Avigen Stockholders To Remove Incumbent Directors and Elect Slate of Stockholder-Focused Nominees
7. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
8. CFSO Calls for Roundtable to Develop National Strategy for Advancing Forensic Sciences in the United States
9. Bauer Calls Taxpayer-Funded Embryonic Stem Cell Research A Tragedy
10. AstraZeneca Calls on All Americans to Join US AGAINST ATHERO to Fight the Nations Number One Killer
11. Xmark Requests That Icagen Oust Its CEO and Pursue Strategic Alternatives, and Calls on Board Members to Resign
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") (en.tusholdings.com) ...
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
Breaking Biology Technology:
(Date:6/20/2016)... DALLAS , June 20, 2016 ... criminal justice technology solutions for public safety, investigation, ... by the prisons involved, it has secured the ... Corrections (DOC) facilities for Managed Access Systems (MAS) ... (4) additional facilities to be installed by October, ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/1/2016)... YORK , June 1, 2016 ... Technology in Election Administration and Criminal Identification to Boost ... to a recently released TechSci Research report, " Global ... By Region, Competition Forecast and Opportunities, 2011 - 2021", ... 24.8 billion by 2021, on account of growing security ...
Breaking Biology News(10 mins):